Skip to main content
Search

Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2

Part 2 of 2
Published on November 28, 2024   19 min

A selection of talks on Cell Biology

Please wait while the transcript is being prepared...
0:00
Welcome back. I'm pleased to see that you have joined for part two of this talk in which I will discuss further the roles of oncolytic viruses, toll-like receptor agonists, and STING agonists in the treatment of patients with cancer.
0:19
Now, I go on to discuss the clinical development of the RP platform. This has been tested in patients with a range of different tumour types including cutaneous melanoma, even in a group of patients who have previously received and progressed following anti-PD1 therapy. Here, I show you the design of a study in which patients initially received a first dose of virus and then virus in combination with nivolumab for a number of cycles, up to 30 cycles of treatment with Opdivo or nivolumab with patients being followed for safety but also to assess the efficacy of the RP1 platform. Remember please that these are patients who have previously shown progression on anti-PD1 therapy.
1:09
Here, you see the breakdown of the demographics of these patients. You can see that there were initially 16 patients treated in the first cohort and then there was an expansion cohort of a further 75 patients, leading to a total population of 91. All of whom had received prior anti-PD1. Some of whom had received also anti-CTLA-4 and other therapies. You can see the breakdown there. This is a group of patients with very advanced disease, the vast majority being stage 4 melanomas in both of these groups and over a quarter of the patients having had a high level of LDH above the upper limit of normal. The treatment is extremely well tolerated and

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2

Embed in course/own notes